S
Wendy Niebler
Vice President, Global Medical Affairs, ADHD, Shire
EDUCATION: DO from Ohio University College ofOsteopathic Medicine, MBA from St. Joseph's University
ACCOMPLISHMENT: Designed Cephalon's largest global clinical program in under two years
On joining the pharma industry:
I started out as a physician in private practice. But the scientific aspect of clinical trial work motivated me to join Cephalon, because I had a chance to not only run, but design, clinical trials. It was an opportunity of a lifetime. As a physician going to industry, you can miss that day-to-day contact with patients. But it's reassuring to know you can impact patients even in a wider sense.
Wendy Niebler
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
FDA Approves Opdivo Plus Yervoy Regimen for MSI-H/dMMR Colorectal Cancer
April 9th 2025Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was the largest immunotherapy study in patients with previously untreated, unresectable, or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.